Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 27Triple Negative Breast Neoplasms 9Sarcoma 5Neoplasm Metastasis 4Liposarcoma 3Urinary Bladder Neoplasms 2Leiomyosarcoma 2Inflammatory Breast Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Refractory Solid Tumors 1Recurrence 1Metastatic HER2-positive Breast Cancer 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HR+HER2- Breast Cancer 1HER2-low Breast Cancer 1Fludzoparib" and Anti-angiogenic 1Colorectal Neoplasms 1Brest Cancer 1Brain Neoplasms 1Advanced Breast Cancer 1

Interventions

Paclitaxel 7Cyclophosphamide 6Doxorubicin 5pembrolizumab 3Trastuzumab 3Taxes 3Specimen Handling 3Carboplatin 3pertuzumab 2eribulin 2Radiotherapy 2Epirubicin 2Docetaxel 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1ruxolitinib 1pegfilgrastim 1onvansertib 1olaparib 1neratinib 1durvalumab 1cobimetinib 1atezolizumab 1X-Rays 1Therapeutics 1Tamoxifen 1Surgical Procedures, Operative 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Panitumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Inflammatory Breast Neoplasms × eribulin × 1 year × Clear all
NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
37 enrolled
Breast

Inflammatory Breast Neoplasms

NCT02623972 2025-11-25

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
22 enrolled 12 charts
Breast

Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡